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Empirical modifications to the Amber/OPLS potential for
predicting the solution conformations of cyclic peptides
by vacuum calculations
Chen Keasar and Rakefet Rosenfeld
Background: Peptides have ubiquitous roles in all biological systems and
are thus of interest in both basic and applied research. The rational design
of bioactive peptides could be greatly enhanced by an efficient method for
accurately predicting the conformations that these molecules can adopt in
solution. As a design process inevitably requires testing numerous
molecules, an efficient method would require the calculations to be
performed in vacuum.
Results: Attempts to predict the conformations of cyclic peptides using a
simulated annealing protocol with the Amber/OPLS potential in vacuum
resulted, not unexpectedly, in overly packed, non-native conformations. We
therefore empirically modified the potential by several cycles of structure
prediction and function refinement until a good fit between experimental and
predicted conformations was obtained. Three major modifications to the
potential were required in order to reproduce the solution structures of cyclic
peptides: explicit torsional energies for the peptide backbone torsional angles;
explicit hydrogen-bonding energies for backbone hydrogen bonds; and a
penalty for close approaches between uncharged and charged atoms.
Conclusions: Using the modified potential, we predicted the solution
conformations of cyclic peptides in the size range of 5–10 residues with
reasonable accuracy.
Introduction
The diverse biological activities of short (< 10 amino
acids) peptides make them attractive for medicinal
research. The large arsenal of naturally occurring peptides
has been tremendously amplified in recent years through
the use of combinatorial chemistry and phage-display
peptide libraries, yet only a few linear peptides are used as
drugs. This is due, at least partially, to the structural flexi-
bility of linear peptides, which commonly leads to weak
affinity, low selectivity and fast rates of degradation.
A common approach to the generation of peptide analogs
with higher therapeutic value is to design conformationally
constrained peptides. A local restriction of conformation
space can be achieved by the introduction of proline or
non-natural conformationally restrained amino acids. Much
more drastic restriction of conformation space is achieved
by creating cyclic analogs of the linear peptides. These
analogs are generally more biostable than the parent linear
molecules, and whereas some of them might be totally
inactive others might display higher potency and improved
selectivity [1,2]. The ability of a cyclic peptide to bind a
target molecule depends on its ability to adopt a specific
conformation compatible with the structure of the binding
site. Thus knowledge of the conformation space available
to a bioactive cyclic peptide can be utilized both to predict
and to optimize its binding properties [2].
The structures that a peptide can adopt in solution and solid
states can be determined by 2D-NMR and X-ray crystallog-
raphy, yet these methods have three major drawbacks: they
are expensive and laborious; they can provide only the most
populated conformations (typically no more than two), at
times failing to see biologically relevant ones; and they are
restricted to peptides that have already been synthesized.
Computational methods for the prediction of constrained
peptide conformations should complement the experi-
mental techniques. Ideally they should be faster, allow a
wide sampling of conformation space and enable investi-
gations of new peptides that exist only in the chemists’
imagination [3]. Accordingly, our aim in the current work
is to develop a fast method for predicting the conforma-
tions of cyclic peptide (or peptide-like) analogs that is
accurate enough to be of practical use. We believe that
such a method is a necessity for the rational design of
bioactive cyclic peptides.
The demand for rapid results dictates a key feature of this
work, namely that solvent is not represented explicitly in
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the calculations. Simulations with explicit solvent are
more accurate — solvent has a profound effect on the
structure and dynamics of cyclic peptides [4–6] — yet are
computationally intensive due to both the size of the
system and the dampening of peptide movements by the
solvent. Our working assumption is that the conforma-
tional restriction imposed by cyclization is severe, and the
solvent can merely modify the occupation of a rather small
set of possible conformations (an assumption that is
mainly true for the backbone of the peptides, and obvi-
ously weakens with increasing ring size and flexibility).
This assumption notwithstanding, our attempts to predict
the experimentally observed conformations of cyclic pep-
tides starting from random conformations and using a stan-
dard simulated annealing protocol with the united atom
Amber/OPLS force field [7,8] in vacuum were unsuccess-
ful. Specifically, we failed to reproduce either the known
backbone dihedral conformational preferences [9,10], or
native-like hydrogen bonding patterns, and our generated
structures were generally more compact than those
observed experimentally.
To remedy this we introduced empirical modifications to
the Amber/OPLS potential that substantially reduce the
occurrence of these non-native structural features.
Coupled to a molecular dynamics simulated annealing
protocol, the modified force field was tested on a set of 21
cyclic peptides differing in sequence, size, and cyclization
mode, whose solution conformations have been deter-
mined experimentally. The results demonstrate that the
modified force field can reproduce with reasonable accu-
racy the experimental results, usually within a small
(n ≤ 10) set of lowest-energy conformations.
Methodology
General
Solution structures of cyclic peptides were predicted by a
molecular dynamics simulated annealing protocol using
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Table 1
Peptides used in this study.
Number (name) Size* Mode of cyclization Sequence and connectivity†
1‡ (PTR3046) 7(6) Backbone to backbone NPhe-Tyr-dTrp-Lys-Thr-NPhe-Thr-NH2
|                                    |
(CH2)3
___CO−NH___(CH2)2
2§ 5(5) Head to tail Cyclo(Pro-Pro-Ala-Ala-Ala)
3§ 5(5) Head to tail Cyclo(Pro-Ala-Pro-Ala-Ala)
4§ 6(6) Head to tail Cyclo(Pro-Pro-Ala-Ala-Ala-Ala)
5§ 7(7) Head to tail Cyclo(Asn-Pro-Phe-Val-Val-Pro-Val)
6# (Veber compound) 6(6) Head to tail Cyclo(Pro-Phe-dTrp-Lys-Thr-Phe)
7# 6(6) Head to tail Cyclo(nPhe-Phe-dTrp-Lys-Thr-Phe)
8§ 6(6) Head to tail Cyclo(dPro-Ala-Ala-dPro-Ala-Ala)
9# (octreotide) 8(6) Disulfide dPhe-Cys-Phe-dTrp-Lys-Val-Cys-Thr-Ol
| |
10¶ (sp1) 7(5) Backbone to N terminus NGly-Arg-Phe-Phe-NGly-Leu-Met-NH2
|                              |
CO                        (CH2)2
|                              |
(CH2)2
___CO___NH
11¥ 4(4) Head to tail Cyclo(dPhe-Pro-Sar-Gly)
12¶(sp2) 6(4) Backbone to N terminus NArg-Phe-Phe-NGly-Leu-Met-NH2
|                        |
CO                 (CH2)3
|                        |
(CH2)4
__CO__NH
13# 6(6) Head to tail Cyclo(nsPhe-Phe-dTrp-Lys-Thr-Phe)
14§ 4(4) Head to tail Cyclo(Phe-Pro-Phe-dPro)
15§ 5(5) Head to tail Cyclo(dPro-Ala-dPro-Ala-Ala)
16§ 6(6) Head to tail Cyclo(dPro-dPro-Ala-Ala-Ala-Ala)
17# 6(6) Head to tail Cyclo(nPhe-Phe-dTrp-Lys-Thr-Gly)
18** 6(6) Head to tail Cyclo(Gly-Tyr-Val-Pro-Met-Leu)
19§ 6(6) Head to tail Cyclo(Arg-Gly-Asp-Phe-Pro-Ala)
20§ 6(6) Head to tail Cyclo(Arg-Gly-Asp-Phe-Pro-Gly)
21†† 10(10) Head to tail Cyclo(Pro-Phe-Phe-Aib-Leu-Pro-Phe-Phe-Aib-Leu)
*Total number of residues (number in ring). †Standard three-letter code
is used for naturally occurring amino acids; d before three-letter code
signifies a D-stereoisomer; Sar, sarcosine (N-methyl-glycine); nPhe,
Phe peptoid residue (sidechain moved from Cα to backbone amide);
N before three-letter code signifies an N-alkylated amino acid; nsPhe,
β-methylated (S) nPhe; Aib, α-amino-isobutyric-acid. ‡A backbone
cyclic peptide; [16]. §Coordinates kindly provided by R. Kornat and H.
Kessler (TUM). #Coordinates kindly provided by R. Mattern and M.
Goodman (UCSD). ¶Substance-P analogs [17]. ¥[18]; **[19]; ††[20].
the molecular modeling package MOIL [11]. Due to the
rigidity of cyclic peptides, structural changes require the
crossing of high-energy barriers and, as these are rare, very
long simulations are needed for an exhaustive conforma-
tional search. To circumvent this requirement we chose to
perform short (100 psec) simulations, starting from an
order of 103 random initial conformations.
We used the Amber/OPLS force field with united atoms
[7,8] and a dielectric constant ε = 20. This force field when
used with explicit solvent (and ε = 1) has proved suitable
for studying structural properties of peptides and proteins
[5,12], yet our simulations clearly demonstrated that it
cannot be directly transferred to vacuum simulations (data
not shown). We therefore empirically modified the force
field using the following iterative strategy.
Initially, we predicted the structures of several peptides
and compared our predictions to the experimental struc-
tures. Then we tried to understand qualitatively what
went wrong, modified the force field accordingly and
tested it again, gradually increasing the size of our learning
set. The modifications as well as the logic behind them
are described below. All peptides predicted are listed in
Table 1. Peptides 1–13 were used in the force-field modi-
fication cycle; the remaining eight peptides were studied
after the last modification of the force field and can be
considered a test set.
Force-field modifications
Torsion angle biases. The backbone torsion angle preferences
observed in proteins and peptides [9,10] were only weakly
reproduced in our solvent-free system and were therefore
encouraged by introducing the following biases explicitly.
Peptide bonds with secondary amines were biased to trans
conformation by two terms: a harmonic term that repre-
sents the preference of primary peptide bonds for the
trans conformation (force constant 1 kcal/mol/rad2) and a
step function of 1 kcal/mol (convoluted with a gaussian for
differentiability) that biases the peptide torsion angle
towards the most populated region in the databases [13]
(180° ± 20°). For peptide bonds with tertiary amines
(proline and N-alkylated amino acids), only the 1 kcal/mol
step function (180° ± 20°; 0° ± 20°) is used to allow both cis
and trans conformations.
The φ and ψ torsion angles of all residues excluding
glycine and its derivatives are biased by a 3 kcal/mol step
function towards their most probable regions of the
Ramachandran plot (Figure 1). The function was convo-
luted with a gaussian centered at the borders of the pre-
ferred areas depicted in Figure 1. Other torsion angles in
the cycle (the disulfide bridges or the bridging arms in
backbone cyclic peptides, see below) are forced out of the
cis conformation (0° ± 20°) by a 3 kcal/mol step function.
In all step functions the width of the gaussians were
chosen such that at a deviation of 10° the energy would
fall to 0.99% of the maximal value.
Hydrogen bonds. Hydrogen bonds are treated implicitly by
the Amber/OPLS potential. When explicit solvent is used,
proper hydrogen bonds are created by the combined
effect of the electrostatic and van der Waals terms. We
failed to restore native-like hydrogen bonds in our
solvent-free system, even after manipulating the dielectric
constant (testing different values and/or distance depen-
dencies). Thus, we introduced an explicit hydrogen-bond
term. Currently, this term is used only for nonterminal
backbone atoms. These are the dominant hydrogen bonds
in the experimentally determined solution structures of
peptides, probably owing to the high propensity of
sidechains and charged termini to create hydrogen bonds
with the solvent. In the current version of our force field,
an ideal hydrogen bond (distance between the carbonyl
oxygen and the amide hydrogen (doh) = 2 Å and the car-
bonyl carbon–amide nitrogen distance (dcn) > 3.5 Å) has an
energy of –3 kcal/mol. Double hydrogen bonds on the
same atoms are allowed, but are scaled down so that the
sum of their energies is < –3 kcal/mol, as these double
hydrogen bonds are rather scarce in peptide solution struc-
tures. The 3 kcal/mol energy well is deeper than that typi-
cally estimated for hydrogen bonds — a possible
consequence of the hydrophobic nature of the solvents
used in most NMR studies.
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Figure 1
Allowed backbone dihedral conformations for non-glycine amino acids.
The ranges of the boxed areas are: top left box: φ = (–30) → (–180),
ψ = (60) → (180); bottom left box: φ = (–40) → (–140),
ψ = (–60) → (45); right box: φ = (20) → (90), ψ = (–30) → (90);
dihedral angles outside these ranges were penalized by 3 kcal/mol.
The inverse image of this map (φ → –φ; ψ → –ψ) was used for the
D-stereoisomers of the amino acids.
180.0 120.0 60.0 0.0 60.0 120.0 180.0
φ
180.0
120.0
60.0
0.0
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180.0
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Hydrophilic term. An amusing artifact of using a united atoms
model in a solvent-free system is the creation of strong con-
tacts between polar (and even charged) atoms and aliphatic
or aromatic ones. Whereas the van der Waals interactions
are favorable, there are no electrostatic interactions (most
aliphatic and aromatic atoms in a united atoms model have
zero charge). In reality (and when simulation is done with
explicit solvent) these interactions are much weaker, as
polar atoms interact with the polar atoms of the solvent.
This artifact was partially alleviated by introducing a gauss-
ian penalty of 1 kcal/mol on the interactions between
charged atoms (including partial charges) and uncharged
atoms. The function is calculated by exp (–f (r – 3.0)2),
where r is the distance between the uncharged and charged
atoms and f was set to 1 kcal/mol in the current version.
Simulations
Initial random conformations. A rigorous test of any force
field is to start from conformations that are very far from any
of the desired endpoints — for example highly distorted
conformations. Such conformations were generated as
follows. Coordinates for the first atom in each residue
(usually the amide nitrogen) were generated by assigning
random x, y and z values between –50 and 50 with equal
probability. The remaining atoms in the residue were
assigned random x, y and z values within 15 Å from the first
atom. The resulting structure was minimized with the con-
jugate gradient algorithm using the standard Amber/OPLS
force field, with the exception that primary peptide bonds
(with NH) were forced to a trans conformation. The mini-
mized conformations typically have energies lower than
400 kcal/mol; conformations with energies higher than
500 kcal/mol are usually geometrically invalid and were
therefore rejected. By repeating this process with different
seeds for the random number generator, an unbiased highly
diverse set of random conformations was generated.
Simulated annealing. 100 ps simulated annealing [14] mole-
cular dynamics simulations were performed using the
Verlet algorithm with SHAKE and a 1 fsec time step.
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Table 2
Lowest-energy conformations (center of cluster) similar to experimental results.
Prediction 1
Peptide number Size NMR conformation* rms (Å)† Rank‡ ∆Ε§ Figure#
1 7(6) 0.55 3 2.1 4
2 5(5) cis–cis 0.24 1 0.0 2
cis–trans 0.29 2 1.6 2
3 5(5) 0.29 1 0.0 2
4 6(6) 0.76 1 0.0 2
5 7(7) 0.59 3 2.1 3
6 6(6) 0.43 1 0.0 3
7 6(6) cis 0.68 1 0.0 3
trans 0.85 3 3.4 3
8 6(6) 0.33 1 0.0 2
9 8(6) 0.33 2 0.07 3
10 7(5) 0.87 5 5.4 4
11 4(4) cis–trans 0.07 10 4.8 2
trans–cis 0.62 1 0.0 2
12 6(4) 0.61 10 4.8 4
13 6(6) cis 0.57 3 2.2 3
trans 0.51 1 0.0 3
14 4(4) 0.16 1 0.0 2
15 5(5) 0.27 2 0.64 2
16 6(6) 0.32 1 0.0 2
17 6(6) cis 0.57 1 0.0 3
trans 0.85 2 4.9 4
18 6(6) cis 0.79 1 0.0 3
trans 0.85 3 2.1 3
19 6(6) cis 0.72 2 2.2 3
trans 0.27 1 0.0 3
20 6(6) cis 0.72 5 4.3 3
trans 0.36 1 0.0 3
21 10(10) 0.61 1 0.0 4
*In several cased more than two conformations were identified
experimentally, having cis/trans isomerization around peptide bonds
preceding N-alkylated amino acids. †Backbone rmsd between the ring
portion of the calculated and experimentally determined conformations.
‡The ranking of the conformation closest to the experimental from among
the 10 lowest-energy conformations calculated. §The energy difference
between the closest conformation and the minimum-energy one. #Figure
in which predicted and experimental conformations are compared.
During each simulation the temperature was reduced lin-
early from 2000 K to 0.01 K. Two modifications were
added to the standard Verlet algorithm to render it more
stable at high temperatures: first, if the average force on an
atom exceeded 200 kcal/mol/Å or if the SHAKE algorithm
failed to converge, 20 steps of steepest decent minimiza-
tion were performed and the simulation continued from
the more relaxed structure; second, if the simulation
‘crashed’, it restarted from a periodically (10 psec) saved
conformation. As the atomic velocities were initialized in
this case, the system did not follow the previous trajectory
and in most cases escaped second failure. It should be
noted that our hydrogen bond energy term is not differen-
tiable at all points. In the rare cases that its value falls on a
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Figure 2
Peptide 2
conformation 1
0.24Å; 1; 0
Peptide 2
conformation 2
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Peptide 3
0.29Å; 1; 0
0.16Å; 1; 0
Peptide 14 Peptide 15
0.27Å; 2; 0.64
Peptide 16
0.32Å; 1; 0
0.07Å; 10; 4.8
Peptide 11
conformation 1
0.62Å; 1; 0
Peptide 11
conformation 2
Peptide 4
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Peptide 8
0.33Å; 1; 0
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Superposition of calculated (thin line) and observed (thick line) conformations for short peptides. All heavy atoms are depicted. Backbone rmsd of ring
residues as well as energy ranking and energy differences from the lowest-energy conformations are shown below the superposition (rmsd; rank; ∆E).
discontinuous point the program fails, and restarts as in
the second case above.
Clustering procedure
A simple clustering procedure was used in the analysis of
the results. For each compound the lowest-energy confor-
mation was considered the center of the first cluster. All
the conformations with backbone rmsds smaller than 0.5 Å
from the lowest-energy conformation were added to its
cluster. Then, the lowest-energy conformation among the
unclustered conformations was chosen as the center of the
next cluster and the process repeated until all conforma-
tions were clustered.
Target compounds
A major obstacle to the systematic development and
testing of prediction methods in the field of cyclic pep-
tides is the absence of a public database of cyclic peptide
structures. The experimentally determined coordinates
for most of the 21 cyclic peptides used in the current
work were generously provided by R. Kornat and H.
Kessler from Technische Universität München and by R.
Mattern and M. Goodmann from the University of Cali-
fornia at San Diego. Few additional structures were taken
from the literature. These were described by torsion
angles in the original papers and were built with the
molecular graphics program INSIGHT [15] followed by
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Figure 3
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Superposition of calculated (thin line) and observed (thick line) conformations for longer peptides with complex sidechains. Data given as in Figure 2.
minimization with DISCOVER. All the peptides used are
listed in Table 1.
Results
One thousand simulated annealing structure optimiza-
tions, each starting from a random initial conformation,
were performed as described in the Materials and
methods section on each of the 21 target peptides listed in
Table 1. The final conformations were then clustered, and
each cluster was represented by its lowest-energy confor-
mation. The representative conformations were sorted by
energy and the ten lowest-energy conformations were
compared with the NMR structures. In cases where the
experimental constraints matched more than one possible
conformation all possible structures were used for compar-
ison. When two structures were observed experimentally
(i.e. two separate sets of nuclear Overhauser effects
(NOEs) were observed) they were each considered sepa-
rately.
Table 2 and Figures 2–4 summarize our results, showing
the lowest-energy conformation that is close to the experi-
mental structure (backbone rmsd < 0.9 Å) from among the
ten minimum-energy conformations calculated, its rank,
and the difference between its energy and that of the
minimum-energy conformation found. The results can be
analyzed at two levels. The first pertains to the overall
backbone conformation of the circular backbone and the
second to the conformation of the entire peptide. On the
first level, we consider our results a success. The overall
backbone conformations of our calculated structures are
close to those observed in solution, and in most cases the
minimum-energy conformation is that closest to the
experimental one (in several cases where the second
minimum-energy conformations is closest its energy dif-
ference from the first is practically 0). Moreover, the
overall results of the test set (peptides 14–21) are as good
as those obtained for the peptides that were used to
modify the force field. This is seen clearly if one com-
pares, for example, peptides 4 and 16 (Figure 2), which
differ only in the replacement of two D-prolines in peptide
16 for the two L-prolines in peptide 4. This result implies
that the modifications we have added to the force field
embrace general features of cyclic peptides rather than
idiosyncrasies of peptides 1–13.
Figure 2 shows the deviations between the calculated and
experimental conformations of the small peptides and
those with few or rigid sidechains. Only 2 of the 10 confor-
mations observed experimentally for these eight peptides
are not found by the simulations — conformation 2 of
peptide 11 and that of peptide 4. Yet despite the relatively
large deviation observed within a small fragment of the
backbone, in each case the overall conformation and the
backbone hydrogen-bonding pattern are very similar to
those observed in solution.
Figure 3 shows the results for the larger and more complex
disulfide-bridged or head-to-tail cyclic peptides. Here too
the overall backbone conformations are found within rea-
sonable accuracy, with the exception of short fragments
within peptides 7, 13 and 17. Yet despite the large devia-
tions within these short fragments, the overall deviations
are reasonable. In all cases the backbone hydrogen bonds
observed experimentally were reproduced in the pre-
dicted conformations.
Figure 4 shows the results for the four most flexible pep-
tides that we tested. Despite the greater flexibility, the
results here are almost as good as those observed for the
more constrained peptides, with the exception of a trans
conformation of compound 10, which was not even
approximated by our simulations (data not shown). The
major deviations observed for peptides 1, 10 and 12 are
in the poly-methylene bridges, which are expected to be
much more flexible than the peptidic region. Yet despite
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Figure 4
Superposition of calculated (thin line) and observed (thick line)
conformations for larger and more flexible peptides. Data given as in
Figure 2. The two N-terminal residues of peptide 10 (sp1) were
removed for clarity.
0.55Å; 3; 2.1
Peptide 1
0.87Å; 5; 5.4
Peptide 10
cis conformation
0.61 Å; 10; 4.8 0.61Å; 1; 0
Peptide12 Peptide 21
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this high flexibility, the predicted peptidic regions of all
three peptides are as accurate as those obtained for the
more rigid peptides shown in Figure 3. The result
obtained for peptide 21 in this set is promising, as its
size — ten residues — is a clear jump from the sizes of
all peptides that were available to us during the force-
field modification stage. Also, it is worth noting that the
gross topology of out-of-the-ring residues was repro-
duced quite well (Figure 5), suggesting that the rigid
ring structure reduces the conformational freedom of
adjacent residues.
If we look at the all-atom deviations of our calculated
structures we find that sidechain rotamers are frequently
mispredicted (Figures 2–4). The fact that correct back-
bone conformations can be found despite erroneous
sidechain rotamers is encouraging, and is a direct result
of the limited conformational space available to these
cyclic peptides. An examination of the calculated
sidechain conformations shows that erroneous rotamers
are often stabilized by van der Waals interactions
between hydrophobic sidechains (peptides 6, 7, 13, 17 in
Figure 3; peptide 1 in Figure 4), indicating that this type
of interaction is over-represented in our system. Addi-
tional errors are observed as a result of improper hydro-
gen-bonding patterns of sidechains (peptide 5). Further
modifications to the force field can correct this, yet
require a larger, more diverse database of experimentally
determined structures.
Discussion
Conformationally constrained peptides are of major inter-
est, both as potential lead compounds for development of
therapeutic agents and in fundamental research on the
structural principles of peptides. Efficient procedures for
the rational design of such peptides require, in our
opinion, computational tools for predicting their structure
quickly, as a design process entails testing large numbers
of possibilities. The premise of our work is that there exist
structural features common to all constrained peptides (in
the size range of the peptides studied here), and that
energy functions used for calculating the structures of
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Figure 5
Four of the peptides have ‘tails’: PTR3046
(a), octreotide (b), sp1 (c) and sp2 (d).
Despite the increased flexibility of these tail
regions their orientations are correctly
predicted by our calculations: a turn for
PTR3046, extended for octreotide and sp2,
and an upward fold on the ring for sp1. Thick
lines, NMR; thin lines, calculated structures.
(a) (c)
(d)(b)
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these peptides can be modified empirically to embrace
these features.
Our own and other work (data not shown) has demon-
strated that calculations in vacuum generally do not
reproduce experimental results. We therefore chose to
modify empirically a commonly used energy function
with the aim of accurately predicting a significant set of
cyclic peptides. We operationally defined accurate pre-
dictions as those in which a reasonable close conformation
(backbone rmsd < 0.9 Å) was found among the ten
lowest-energy conformations. This choice is arbitrary yet,
as Figures 2–4 show, the cutoff of 0.9 results in backbone
conformations that resemble the experimental structures
to a large degree, and the choice of ten conformations is
clearly one that commonly used programs for investigat-
ing structure–activity relations can deal with. Thus,
despite the mispredicted sidechains observed in
Figures 2–4 our results can be of practical use. For
example PTR3046 (peptide 1), octreotide (peptide 9) and
the Veber compound (peptide 6) are all analogs of
somatostatin and are known to bind the same receptor. If
we assume that the structure of the consensus somato-
statin biophore (Tyr/Phe–D-Trp–Lys–Val/Thr) must be
in similar conformations in all of these analogs and we
overlap the ten minimum-energy conformations of each
compound with those of the other two, we identify con-
formations very close to the experimentally observed
ones, not only in backbone but also in sidechain orienta-
tions (Figure 6).
It is clearly trivial to modify empirically a potential func-
tion to reproduce the conformation of one specific peptide.
Modifying the potential to reproduce several different pep-
tides is more difficult, and entails capturing features that
are common to all. As this was our aim we did not prede-
fine a learning and test set, but simply started by simulat-
ing one peptide (PTR3046), optimizing the potential
based on a qualitative comparison between the calculated
and observed structures, and proceeded to the next
peptide. Our assumption was that once we captured
enough general features, additional peptides tested would
either show further modifications to be unnecessary, or
that each additional modification improves only a subset of
all the peptides. After testing the first four peptides in
Table 1 both these scenarios were observed, and despite
testing of a large number of additional peptides further
modifications could not be justified.
It is clear that additional modifications aimed at improv-
ing sidechain conformations should be added, but these
should be based on many more diverse sequences. Two
reasonable aspects for consideration are the over-
estimation of van der Waals interactions between
hydrophobic sidechains and the underestimation of
sidechain hydrogen bonds.
Materials and methods
Hydrogen bond energies
An optimal hydrogen bond is defined for backbone atoms in which the
distance between carbonyl oxygen and amide hydrogen (doh) = 2 Å
and the carbonyl carbon–amide nitrogen distance (dcn) > 3.5 Å. For
every residue i, a hydrogen bond is defined between the carbonyl
oxygen of i and all amide nitrogens for which (dcn) = 3.5 Å, excluding
those of residues i, i+1 and i+2. The hydrogen bond energies are cal-
culated as follows:
For each potential hydrogen bond i we define
Ei(oh) = exp(–(doh–2.0)2)
Fi(oh) = –2 Ei(oh) (doh–2.0)
and
Ei(cn) = exp(–8(dcn–3.5)2)
Fi(cn) = –16 Ei(cn) (dcn –3.5).
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Figure 6
Conformations close to those observed experimentally could be
identified for PTR3046, octreotide and the Veber compound by
assuming that their similar activities imply a similar conformation for the
somatostatin analog consensus sequence Tyr/Phe–D-Trp–Lys–Val/Thr
(shown in thick lines). For all three analogs the backbone rmsds
between the depicted conformations and those observed
experimentally are < 0.4 Å.
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The energy of hydrogen bond i, Ei, is defined as
Ei = – Ei(oh)(1– Ei(cn))
Finally, the energies and forces for all hydrogen and oxygen atoms is
defined by
Ehj = Σ Ei (summed over all hydrogen bonds i that involve
hydrogen atom j)
Eoj = Σ Ei (summed over all hydrogen bonds i that involve
oxygen atom j)
Fhj = Σ Fi(oh) * (Ei(cn) –1)* uoh
Foj = Σ Ei(oh) *Fi(cn)* ucn
where u is the corresponding unitary vector.
A scaling factor, scale, is defined to account for multiple hydrogen
bonds on the same atom
if Ehj < –1 scale = (Ehj)–4 else scale =1
if Eoj < –1 scale = (Eoj)–4 else scale =1
and the above energies and forces assume their final form
Ei = scale * Ei * hbond_energy
Fhj = scale * Fhj * hbond_energy
Foj = scale * Foj * hbond_energy
Where hbond_energy was defined herein to equal 3 kcal/mol.
Note that the scaling of multiple hydrogen bonds results in a discontin-
uous energy function. Therefore the forces were not calculated directly
from the scaled energies but approximated by scaling the derivatives of
the unscaled energies.
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